心肌收缩力调节器治疗慢性心力衰竭的临床应用进展  

Clinical application progress of cardiac contractility modulation in treatment of chronic heart failure

作　　者：林小涵 刘宴宗 张欣宁 杜文娟[1] 徐健[1] LIN Xiao-han;LIU Yan-zong;ZHANG Xin-ning;DU Wen-juan;XU Jian(Department of Cardiology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属第二医院心血管内科,黑龙江省哈尔滨市150000

出　　处：《中国心血管病研究》2025年第1期91-96,共6页Chinese Journal of Cardiovascular Research

摘　　要：心脏收缩力调节器(CCM)作为一种新型的治疗手段,突破了心力衰竭(心衰)患者器械治疗的局限性,尤其适用于那些药物治疗效果不佳且不符合心脏再同步化治疗(CRT)植入标准的患者。CCM通过在心脏绝对不应期施加电刺激,增强细胞内钙离子水平,从而提高心肌收缩力,同时改善心室重构而不增加心肌耗氧。目前,多项临床研究表明,CCM能够显著改善心衰患者的心功能、提高生活质量并减少住院率。此外,其在治疗过程中具有良好的安全性,严重不良事件较少发生。本综述对CCM的作用机制、临床疗效及安全性进行了全面探讨。Cardiac contractility modulation(CCM),as a novel therapeutic approach,addresses the limitations of device-based treatment for heart failure,particularly for patients who do not respond adequately to medication and do not meet the criteria for cardiac resynchronization therapy(CRT)implantation.CCM delivers electric signals during the absolute refractory period of the heart,enhancing intracellular calcium levels to increase myocardial contractility while improving ventricular remodeling without increasing myocardial oxygen consumption.Current clinical studies have demonstrated that CCM significantly improves cardiac function,enhances quality of life and reduces hospitalization rates in heart failure patients.Additionally,it shows a favorable safety profile,with few severe adverse events reported during the treatment.This paper comprehensively reviews the mechanism,clinical efficacy and safety of CCM.

关 键 词：心肌收缩力调节器 心力衰竭 器械治疗 

分 类 号：R541.6[医药卫生—心血管疾病]